Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones

Core Insights - Glucotrack, Inc. is preparing to submit an Investigational Device Exemption (IDE) to the U.S. FDA for its continuous blood glucose monitoring (CBGM) technology, aiming for submission in Q2 2026 [1] Group 1: Operational Milestones - The company completed its first-in-human study in Brazil, which involved ten participants with diabetes, demonstrating successful insertion and removal of the device [3] - The study achieved a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched pairs, with a 99% data capture rate and no serious adverse events [4] - A follow-up feasibility clinical trial was initiated in Australia, providing valuable insights for future studies [5] Group 2: Market and Commercial Strategy - Extensive U.S. market research indicates a significant unmet need for a fully implantable CBGM solution, highlighting the potential for a scalable impact on millions of diabetes patients [2] - The company has identified a clear U.S. reimbursement pathway and established a dual-source manufacturing strategy with qualified partners [2] - A seasoned management team with experience from industry leaders has been assembled to support the company's growth [2] Group 3: Clinical Trial Readiness - Key activities for U.S. clinical trial readiness have been completed, including securing a trial site and engaging a Clinical Research Organization experienced in diabetes Medtech [6] - Discussions with the FDA regarding the planned U.S. clinical trial program are ongoing, with expectations to initiate the study in the second half of 2026, pending FDA approval [7] Group 4: Intellectual Property - The company was awarded three critical patents for its CBGM platform, enhancing its intellectual property portfolio and supporting its go-to-market strategy [8][9]